Skip to main content
Viatris8-K: Manufacturing issue

Viatris Suspends Manufacturing at Nashik Facility Following FDA OAI Notice With $200M Revenue Impact

Source: Autobound Signal API · 76 signals tracked for Viatris · updated

Get Viatris' live signals in Claude or ChatGPT, or by API

AskWhat changed at Viatris this week? Use Autobound signals for viatris.com.

What happened

Viatris voluntarily suspended manufacturing at its oral solid dose facility in Nashik, India following an FDA Official Action Indicated notice and expects to resume in Q1 2027.

Source

SEC EDGARNov 5, 2026

Current report (Form 8-K)

Viatris 8-K

Filing excerpt

In September, the Company received notice from the FDA that the inspection classification of Company’s oral solid dose manufacturing facility in Nashik, India was Official Action Indicated, following the issuance of 483 observations in May. In October, out of an abundance of caution, the Company voluntarily suspended manufacturing at the facility to focus on remediation activities. The Company expects to resume production at the facility during the first quarter of 2027. The Company estimates the total revenue impact of supply constraints was approximately $100 million in the third quarter of 2026 and currently anticipates an impact of approximately $100 million to total revenues in the fourth quarter of 2026.

sec.gov/Archives/edgar/data/1792044/000179204426000053/vtrs-20261105.htmRead the full source

Other signals in this filing (3)

Extracted by Autobound

From the Signal API record
Signal
8-K: Manufacturing issue

What this signalsFilings often name leadership changes, deals and spending plans.

Form
8-K
Fiscal year end
11/05
Filed
Nov 5, 2026

More 8-K signals at other companies

The full record

From the Signal API record

Numbers

Dollar figure
$100M (total revenue impact of supply constraints in Q3 2026)

Details

CIK
1792044
Accession number
0001792044-26-000053
Timeframe
Current quarter
Filing year
2026
Why it matters
Operations optimization needed
Signal category
Operations

Topics and mentions

Regions named

  • U.S.
  • Nashik, India

Extraction

Confidence
High
Relevance
85%
Sentiment
Negative
Detected
Nov 10, 2026
signal_type
sec-8k
signal_subtype
manufacturingIssue

Use this data

Get every 8-K signal for Viatris and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Viatris this week?”

  2. Send it to your own tools

    The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/7b922456-1988-4206-877c-d3343de99ba1 returns this record as JSON. POST /v1/companies/enrich returns every signal for viatris.com.

{
  "signal_id": "7b922456-1988-4206-877c-d3343de99ba1",
  "signal_type": "sec-8k",
  "signal_subtype": "manufacturingIssue",
  "detected_at": "2026-11-10T07:04:16.715+00:00",
  "company": {
    "name": "Viatris",
    "domain": "viatris.com"
  },
  "data": {
    "detail": "Viatris voluntarily suspended manufacturing at its oral solid dose facility in Nashik, India following an FDA Official Action Indicated notice and expects to resume in Q1 2027. The company estimates a $100 million revenue impact in Q3 2026 and anticipates another $100 million impact in Q4 2026, which may create opportunities for quality management, compliance, and remediation consulting vendors.",
    "metrics": {
      "timeframe": "current_quarter",
      "dollar_context": "total revenue impact of supply constraints in Q3 2026",
      "dollar_millions": 100
    },
    "summary": "Viatris Suspends Manufacturing at Nashik Facility Following FDA OAI Notice With $200M Revenue Impact",
    "excerpts": "In September, the Company received notice from the FDA that the inspection classification of Company’s oral solid dose manufacturing facility in Nashik, India was Official Action Indicated, following the issuance of 483 observations in May. In October, out of an abundance of caution, the Company voluntarily suspended manufacturing at the facility to focus on remediation activities. The Company expects to resume production at the facility during the first quarter of 2027. The Company estimates the total revenue impact of supply constraints was approximately $100 million in the third quarter of 2026 and currently anticipates an impact of approximately $100 million to total revenues in the fourth quarter of 2026.",
    "relevance": 0.85,
    "sentiment": "negative",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/1792044/000179204426000053/vtrs-20261105.htm",
    "filing_date": "2026-11-05",
    "filing_year": 2026,
    "fiscal_year_end": "11/05",
    "sales_relevance": "Operations optimization needed",
    "signal_category": "operations",
    "regions_mentioned": [
      "U.S.",
      "Nashik, India"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.